Baird's Investment Banking Group is pleased to announce the following transaction:

August 2021
LivaNova PLC
Follow-on Offering
Baird served as a co-manager on this offering
$345.000 Million

LivaNova PLC (“LivaNova” or the “Company”) (NASDAQ-GS:LIVN) recently completed an underwritten public offering of 4,181,818 shares of its common stock at a public price of $82.50 per share, including the exercise in full by the underwriters of their option to purchase an additional 545,454 shares of common stock at the public offering price. LivaNova anticipates using the net proceeds from the offering to refinance a portion of its term loan.

LivaNova is a global medical device company focused on the development and delivery of important therapeutic solutions for the benefit of patients, healthcare professionals and healthcare systems throughout the world. Working closely with a global team of medical professionals in the fields of cardiovascular disease and neuromodulation, LivaNova designs, develops, manufactures, and sells innovative therapeutic solutions that are consistent with its mission to improve patients’ quality of life, increase the skills and capabilities of healthcare professionals and minimize healthcare costs. LivaNova is comprised of two principal business franchises, which are also its reportable segments: Cardiovascular and Neuromodulation, corresponding to their primary therapeutic areas. LivaNova is headquartered in London, the United Kingdom.

For additional information about this transaction, please contact:

Rob Andrews +1-312-609-5489
Lance Lange +1-414-765-7079
Ryan Engelhardt +1-414-298-2637
Matt Gailey +1-414-765-1458
Andrew Nicholson +44-20-7667-8509